Saturday, October 13, 2007 12:15:40 PM
The phrase Big Pharma is often used to refer to companies with revenue in excess of $3 billion, and/or R&D expenditure in excess of $500 million, and represents the first 30 or so companies in this list (see below). (http://en.wikipedia.org)
Revenue 2006 530 billion (if I added correctly)
PPHM potential Revenue (Just My Opioion):
Virus known classified
(4,000 to 5000) 2000 @ 275 mill each =550b
Cancer 20b
Vta 3b
Vea 3b
Cotara 1b
All Other (knock yourself out) ?b
Total 577b
Revenue Rank 2006 Company Country Healthcare Revenue 2006 (USD millions)
1 Johnson & Johnson USA 53,324
2 Pfizer USA 48,371
3 GlaxoSmithKline United Kingdom 42,813
4 Novartis Switzerland 37,020
5 Sanofi-Aventis France 35,645
6 Hoffmann–La Roch Switzerland 33,547
7 AstraZeneca United Kingdom 26,475
8 Merck & Co. USA 22,636
9 Abbott Laboratories USA 22,476
10 Wyeth USA 20,351
11 Bayer Germany 18,216
12 Bristol-Myers Squibb USA 17,914
13 Eli Lilly and Co. USA 15,691
14 Amgen USA 14,268
15 Boehringer Ingelheim Germany 13,284
16 Schering-Plough USA 10,594
17 Baxter International USA 10,378
18 Takeda Pharmaceutical Co.Japan 10,284
19 Genentech USA 9,284
20 Procter & Gamble USA 8,964
21 Teva Pharmaceutical Israel 8,408
22 Astellas Pharma Japan 7,850
23 Daiichi Sankyo Japan 7,158
24 Novo Nordisk Denmark 6,520
25 Eisai Japan 5,583
26 Merck KGaA Germany 5,175
27 Alcon Switzerland 4,897
28 Akzo Nobel Netherlands 4,694
29 UCB Belgium 4,426
30 Nycomed Switzerland 4,264
31 Forest Laboratories USA 3,442
32 Solvay Belgium 3,268
33 Genzyme USA 3,187
34 Allergan USA 3,063
35 Gilead Sciences USA 3,026
36 CSL Australia 2,788
37 Chugai Pharmaceutical Japan 2,787
38 Biogen Idec USA 2,683
39 Bausch & Lomb USA 2,292
40 Taisho Pharmaceutical Japan 2,069
41 King Pharmaceuticals USA 1,989
42 Watson Pharmaceuticals USA 1,979
43 Mitsubishi Pharma Japan 1,945
44 Shire UK 1,797
45 Cephalon USA 1,764
46 Dainippon Sumitomo Pharma Japan 1,763
47 Kyowa Hakko Kogyo Japan 1,698
48 Shionogi & Co. Japan 1,640
49 Mylan Laboratories USA 1,612
50 H. Lundbeck Denmark 1,552
Source: Top 50 pharmaceutical companies, MedAdNews, September 2007
S.P.
Recent CDMO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:50:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
FEATURED POET Technologies Reports Second Quarter 2024 Financial Results • Aug 15, 2024 8:04 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
ATWEC Reaches Profitability, Announces Massive Earnings Growth, and a Strong Forecast for the Rest of 2024 • ATWT • Aug 15, 2024 7:16 AM